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ABSTRACT
The aim of this study was to identify novel liver metastasis-correlated proteins 
of PanNEN by proteomics to compare pancreatic tumor (PT) with paired metastatic 
liver tumor (LT). Of 118 surgical cases with PanNEN, 7 cases with formalin-fixed 
paraffin-embedded (FFPE) tissues of both PT and paired LT were evaluated by 
proteomics. Tumor cells were selectively collected from FFPE tissues by laser capture 
microdissection. A total of 3,722 proteins were detected from extracted peptides 
by mass spectrometry-based shotgun analysis. Selection of the candidate proteins 
expressed differently between PT and LT were performed by semi-quantitative 
comparison in silico and confirmation with immunohistochemistry. We focused on 
ANXA6, CNPY2, RAB11B and TUBB3, all of which had higher expressions in LT. In all 
surgical cases with FFPE samples, liver recurrence-free survival (RFS) was evaluated in 
correlation to the expression of the candidate proteins in PT by immunohistochemistry. 
Liver RFS was significantly poorer in CNPY2 positive patients than in negative patients 
(10-year liver RFS; 39.8% vs. 92.3%, p = 0.012). Also, liver RFS tended to be poorer 
in ANXA6 positive patients than in those who were negative (10-year liver RFS; 51.4% 
vs. 95.0%, p = 0.099). In the multivariate analysis, the independent predictors of liver 
RFS were CNPY2 positivity (HR: 6.19, 95 % CI: 1.47–42.79, p = 0.011) and tumor 
size ≥ 42 mm (HR: 4.63, 95 % CI: 1.03–23.23, p = 0.045). In conclusion, CNPY2 is a 
novel liver metastasis-correlated protein of PanNEN.
INTRODUCTION
Neuroendocrine tumors (NET) are relatively rare 
neoplasms. However, the number of patients with NET has 
recently been increasing all over the world [1, 2]. In Japan, 
the incidence of pancreatic neuroendocrine neoplasm 
(PanNEN) has been reported to be increasing, showing a 
1.2-fold increase from 2005 to 2010 [3]. Among NETs of 
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various organs, the prognosis of PanNEN is poorer [3]. 
Liver metastasis, found in 42.0% at the initial diagnosis, 
is one of the poor prognostic factors of PanNEN [3]. 
The molecular mechanism, promotors, and inhibitors of 
liver metastasis of PanNEN are mostly unknown. Liver 
metastasis of PanNEN is generally treated with liver 
resection, chemotherapy, peptide receptor radionuclide 
therapy (PRRT), and so on. Several reports have shown 
that the five-year survival rate after liver resection for 
PanNEN is 61–76%, and the liver recurrence rate is 54–
94% at 5 years after prior liver resection [4–7]. Thus, it is 
difficult to obtain cure by hepatectomy for liver metastasis 
of PanNEN. Also, the efficacy of non-surgical treatment 
for metastatic PanNEN is limited. Therefore, since new 
treatment strategies are required to improve the prognosis 
of PanNEN with liver metastasis, it is very important to 
identify novel liver metastasis-correlated molecules of 
PanNEN.
Recently, novel biomarkers or target proteins of 
metastasis in several malignancies, such as pancreatic 
cancer, bile duct cancer, colorectal cancer, and lung 
cancer, have been identified by proteomics using clinical 
samples [8–14]. Prognostic or metastasis-correlated 
proteins have been examined by proteomic analyses 
between the primary tumor and metastatic tumor in colon 
or lung cancer [13, 14]. However, only two studies on the 
proteomics of PanNEN have been reported. One was a 
proteomic analysis between insulinoma with and without 
lymph node metastases [15], and the other one between 
the tumor tissue of insulinoma and normal tissue [16]. 
There has been no study of proteomic analysis comparing 
the primary tumor of PanNEN with liver metastasis. The 
aim of the present study was to elucidate novel liver 
metastasis-correlated proteins of PanNEN by proteomic 
analysis to compare the primary tumor with the paired 
liver metastasis.
RESULTS
Discovery stage
Protein identification by shotgun proteomics and semi-
quantitative comparison
Both primary pancreatic tumor (PT) and paired 
metastatic liver tumor (LT) samples of 7 cases with 
PanNEN were investigated by proteomic analysis to 
determine differences between their protein expressions 
(Figure 1 and Table 1). A total of 3,722 proteins, including 
2,622 proteins in PT and 2,993 in LT, were identified 
by shotgun proteomics (Figure 2A). Seven hundred and 
twenty-nine proteins (19.6%) were identified in PT alone, 
while there were 1,100 proteins (29.6%) in LT alone. 1,893 
proteins (50.8%) overlapped. All of the 3,722 proteins 
identified by shotgun proteomics were compared semi-
quantitatively using spectral counting methods (Figure 2B). 
Based on Rsc >1 or <-1, and statistical significance (p < 
0.05 by G-test), 33 and 76 proteins were overexpressed in 
PT and LT, respectively, were selected. Of these proteins, 
Figure 1: Study flow chart of the sample selection. The study was performed in two stages, a discovery stage for shotgun proteomics 
by LC-MS/MS and a clinicopathological analysis stage for analysis by IHC and multivariate analysis of liver recurrence.
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Figure 2: Selection of the candidate proteins. (A) Venn diagram of proteins detected by shotgun proteomics. (B) Flowchart of the 
candidate proteins selection. All of the 3,722 proteins identified by shotgun proteomics were semi-quantitatively analyzed by the spectral 
counting method and were narrowed down to 109 proteins. Next, 10 candidate proteins, including 3 and 7 proteins overexpressed in PT 
and LT, respectively, were selected from among 109 proteins by a literature review on biological role and relevance of malignant disease.
Table 1: Patient characteristics examined by proteomics
Case Age Gender LT WHO 2017 
Grade
Ki-67 (%) Function 
type
Primary tumor 
diameters (mm)
RFS 
(months)
Prognosis 
(OS, months)
1 53 Male synchronous G2 5.0 NF 14 - Alive (89.3)
2 49 Female synchronous G3 30.5 NF 70 - Alive (73.1)
3 63 Female synchronous G3 25.0 NF 46 - Alive (55.2)
4 69 Male synchronous G2 8.0 NF 75 - Dead (72.7)
5 53 Male metachronous G1 2.7 Gastrinoma 50 25.4 Dead (87.0)
6 75 Male metachronous G2 11.1 NF 150 24.6 Dead (80.0)
7 25 Male synchronous G3 24.5 NF 40 - Dead (77.7)
Abbreviations: NF: non-functioning; RFS: recurrence-free survival; OS: overall survival.
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we focused on 3 and 7 proteins overexpressed in PT 
and LT, respectively, as candidate proteins potentially 
associated with malignant disease, referring to previous 
reports, and so on (Table 2).
Validation of protein expression by immunohistochemistry
In order to confirm the results of proteomic 
analysis, the expressions of 10 candidate proteins in 
samples from the discovery stage were evaluated by 
immunohistochemistry (IHC). Only Histone H3.1 
(HIST1H3A) was expressed at the nuclear level, and 
the others were at the cytoplasm and/or cell membrane 
level. One protein was not immunoreactive, but the 
others, which were positive in the tumor cells, could 
be evaluated. Comparing the protein expressions 
between the tumors and background normal tissue, 
or PT and paired LT, Annexin A6 (ANXA6), the 
canopy FGF signaling regulator 2 (CNPY2), Ras-
related protein Rab-11B (RAB11B) and Tubulin beta-
3 chain (TUBB3) were the most compatible with the 
results of the proteomic analysis, and were expressed 
higher in LT than in PT (Figure 3). These 4 proteins 
were chosen as candidate liver metastasis-correlated 
proteins for the next clinicopathological analysis 
stage, which evaluated the correlationship between the 
expression of the candidate proteins by IHC and the 
clinicopathological factors in the surgically resected 
cases with PanNEN.
Table 2: List of the candidate proteins selected by shotgun proteomics and semi-quantitative comparison
UniProt Accession 
Number
Official 
Symbol
Fold 
Change
Function by Gene Ontology 
Annotation Database
Related pathway by KEGG 
PATHWAY Database
Selected overexpressed proteins in pancreatic tumor
P62491 RAB11A 2.8 GTP binding; GTPase activity; 
Microtubule binging; Myosin V 
binding; Protein binding
Endocrine and other factor-regulated 
calcium reabsorption; Endocytosis; 
Pancreatic secretion: Vasopressin-
regulated water reabsorption
F5H7S3 TPM1 6.6 Actin biding; Cytoskeletal protein 
binding; Structural constituent 
of cytoskeleton; Structural 
constituent of muscle
MicroRNAs in cancer; Cardiac muscle 
contraction; Adrenergic signaling in 
cardiomyocytes etc.
Q15836 VAMP3 3.9 Protein binding; SNAP receptor 
activity; SNARE binding
Phagosome; SNARE interactions in 
vesicular transport
Selected overexpressed proteins in liver tumor
P08133 ANXA6 2.2 GTP binding; calcium-dependent 
phospholipid binding; calcium-
dependent protein binding etc.
No hits
Q9Y2B0 CNPY2 2.2 Protein binding No hits
P68431 HIST1H3A 2.1 Cadherin binding; histone 
binding; nucleosomal DNA 
binding; protein binding
Transcriptional misregulation in 
cancer; Alcoholism; Systemic lupus 
erythematosus
Q15691 MAPRE1 2.3 RNA binding; cadherin binding; 
identical protein binding; 
microtubule plus-end binding; 
protein C-terminus binding etc.
No hits
Q15907 RAB11B 2.1 GDP binding; GTP binding; 
GTPase activity; cadherin 
binding; myosin V binding; 
protein binding
Endocytosis; AMPK signaling 
pathway; Vasopressin-regulated water 
reabsorption
P67812 SEC11A 3.2 Peptidase activity; serine-type 
peptidase activity
Protein export
Q13509 TUBB3 5.1 GTP binding; GTPase activity; 
Protein binding; Structural 
constituent of cytoskeleton
Phagosome; Gap junction; Pathogenic 
Escherichia coli infection
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Clinicopathological analysis stage
Patients’ characteristics
Of 118 PanNEN patients who received surgical 
resection between 1994 and 2016 at Tohoku University 
Hospital, 70 patients, excluding 48 without available 
formalin-fixed paraffin-embedded (FFPE) samples, were 
examined (Figure 1). Table 3 shows the clinicopathological 
background of the patients. The expression of the 
candidate proteins in PT was evaluated in patients with 
or without liver metastasis (Supplementary Figure 1). 
Synchronous and metachronous liver metastasis was seen 
in 8 (11.4%) and 12 cases (17.1%), respectively. No liver 
metastasis was observed in 50 cases (71.4%). High-grade 
in the WHO 2017 grade, Ki-67 labeling index, mitotic 
count, tumor size, vascular and lymphatic invasion rates 
and stage (European Neuroendocrine Tumor Society: 
ENETS) were significantly higher in the synchronous and 
metachronous metastasis groups (WHO 2017 grade: p = 
0.002; Ki-67: p = 0.003; mitotic count: p = 0.017; tumor 
size: p = 0.001; vascular invasion: p < 0.001; lymphatic 
invasion p = 0.002; stage: p < 0.001).
In the IHC analysis, normal islet cells had negative 
expression of CNPY2 and positive expression of ANXA6, 
RAB11B and TUBB3 (Figure 4). The expression of these 
candidate proteins was not detected in normal exocrine 
tissue of the pancreas (Figure 4).
Correlationship between expression of candidate 
proteins and clinicopathological factors
In the immunohistochemical analysis for the candidate 
proteins, the positive expression rate of CNPY2 was 
significantly higher in both the synchronous and metachronous 
liver metastasis groups (p = 0.001). The WHO2017 histological 
grade was significantly correlated with the expression of 
CNPY2 (NET G1: 45.2%, NET G2: 48.5%, NET G3: 100.0%, 
Figure 3: Representative pictures of IHC for the candidate proteins in PT and paired LT. The protein expressions of 
ANXA6, CNPY2, RAB11B and TUBB3 were confirmed in the patients evaluated with proteomics by IHC. ANXA6, CNPY2, RAB11B 
and TUBB3 are IHC images of patient NO.6, 4, 2 and 3, respectively. Scale bars indicate 100 μm.
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p = 0.044) and RAB11B (NET G1: 35.5%, NET G2: 57.6%, 
NET G3: 100.0%, p = 0.010) (Supplementary Table 1). 
RAB11B positive cases were significantly higher in the Ki-67 
labeling index compared with the negative cases (p = 0.005) 
(Supplementary Table 2). None of the immunostained proteins 
was correlated with the tumor size.
Liver recurrence-free survival and multivariate 
analysis
To evaluate overall survival (OS) and liver 
recurrence-free survival (RFS) after surgical resection for 
primary pancreatic tumors, 62 cases without synchronous 
liver metastasis were investigated. OS and liver RFS were 
compared between the positive and negative expression 
of the candidate proteins. There was no significant 
correlation between OS and any of the candidate proteins 
(Supplementary Figure 2). Liver RFS was significantly 
poorer in the CNPY2 positive patients than in those who 
were negative (10-year liver RFS; 39.8% vs. 92.3%, p = 
0.012). Also, liver RFS tended to be poorer in the ANXA6 
positive patients than in the negative patients (10-year 
liver RFS; 51.4% vs. 95.0%, p = 0.099) (Figure 5). The 
expression of RAB11B and TUBB3 had no correlationship 
with liver RFS.
Predictive factors for liver RFS were examined 
by Cox proportional hazard analysis. The cut-off values 
of the Ki-67 labeling index and tumor size associated 
with liver RFS were investigated by receiver operating 
characteristic (ROC) curve analysis. The cut-off values of 
the Ki-67 labeling index and tumor size were 8.2% (area 
under the curve (AUC) = 0.708, p = 0.005), and 42 mm 
(AUC = 0.671, p = 0.010), respectively. As shown in Table 
4, significant factors by univariate analysis included Ki-
67 ≥ 8.2% (p = 0.009), tumor size ≥ 42 mm (p = 0.007), 
vascular invasion (p = 0.009), lymphatic invasion (p = 
0.012) and CNPY2 positive (p = 0.010). ANXA6 was 
likely to be a predictive factor in the univariate analysis 
(p = 0.064). Significant factors in the univariate analysis 
were investigated for the multivariate analysis. In the 
multivariate analysis, the independent predictors of liver 
RFS were CNPY2 positivity (hazard ratio (HR): 6.19, 
95% confidence interval (95% CI): 1.47–42.79, p = 0.011) 
and tumor size ≥ 42 mm (HR: 4.63, 95% CI: 1.03–23.23, 
p = 0.045).
Table 3: Patient characteristics in the clinicopathological analysis stage
Factors Synchronous liver 
metastasis (n = 8)
Metachronous liver 
metastasis (n = 12)
Non-liver metastasis  
(n = 50)
p value
Gender (male: female) 5: 3 7: 5 23: 27 0.595
Age (median±SD) 51±15.5 53±12.8 58±17.9 0.478
Function type NF/ insulinoma/ 
gastrinoma/ glucagonoma (%)
7/0/1/0 (87.5/0/12.5/0) 8/ 2/ 1/ 1 (66.7/ 16.7/ 
8.3/ 8.3)
33/ 15/ 1/ 1 (66.0/ 30.0/ 
2.0/ 2.0)
0.054
WHO 2017 Grade G1/ G2/ G3 (%) 0/5/3 (0/62.5/37.5) 4/ 6/ 2 (33.3/ 50.0/ 
16.7)
27/ 22/ 1 (54.0/ 44.0/ 2.0) 0.002
Ki-67 (median, range) 9.0 (2.0–30.5) 9.7 (1.1–80.0) 2.6 (0.1–25.2) 0.003
Mitotic count (median, range) 2 (1–7) 1 (0–8) 1 (0–14) 0.017
Tumor size (mm, median, range) 48 (14–75) 27 (10–150) 18 (6–70) 0.001
Lymph node metastasis Positive: 
Negative (positive rate, %)
3: 5 (37.5) 3: 9 (25.0) 6: 44 (12.0) 0.100
Vascular invasion Positive: 
Negative (positive rate, %)
8: 0 (100.0) 9: 3 (75.0) 15: 35 (30.0) <0.001
Lymphatic invasion Positive: 
Negative (positive rate, %)
5: 3 (62.5) 7: 5 (58.3) 9: 41 (18.0) 0.002
Stage (ENETS) I: II: III: IV 0: 0: 0: 8 3: 6: 3: 0 23: 21: 6: 0 <0.001
Follow up period (Months, median, 
range)
75.4 (48.4–146.3) 54.8 (14.5–157.5) 57.6 (6.4–239.0) 0.206
Expression in PT; ANXA6 (%) 6 (75.0) 11 (91.7) 31 (62.0) 0.157
Expression in PT; CNPY2 (%) 7 (87.5) 10 (83.3) 19 (38.0) 0.001
Expression in PT; RAB11B (%) 5 (62.5) 6 (50.0) 25 (50.0) 0.864
Expression in PT; TUBB3 (%) 2 (25.0) 8 (66.7) 31 (62.0) 0.126
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DISCUSSION
Liver metastasis of NETs is an independent 
prognostic factor, regardless of the primary organ [3]. 
Liver metastasis was found at the initial diagnosis in 
40–45% of the patients with NETs of the small intestine, 
pancreas, and colon [3]. Although the development of new 
drug treatments is needed to improve the prognosis in liver 
metastasis of PanNEN, the mechanisms of liver metastasis 
of PanNEN remain unclear.
It is important to detect some specific novel proteins 
that are strongly expressed or inhibited in liver metastasis 
of PanNEN for clarifying the mechanism, preventing 
the onset and improving treatment. For this purpose, we 
compared the protein expression between the primary 
tumor and the paired liver metastasis using proteomic 
analysis in the present study. There has been no study 
about discovery of novel liver metastasis-correlated 
proteins of PanNEN by proteomic analysis. However, 
we previously succeeded in detecting new biomarkers of 
Figure 4: Representative pictures of IHC for the candidate proteins in normal pancreatic tissue. (A) ANXA6, (B) CNPY2, 
(C) RAB11B, (D) TUBB3. Expression of CNPY2 was negative in normal islet cells (B: arrow). ANXA6, RAB11B and TUBB3 had 
positive expression in normal islet cells. Expression of ANXA6, CNPY2, RAB11B and TUBB3 was not detected in normal exocrine tissue 
of the pancreas. Scale bars indicate 100 μm.
Figure 5: Liver recurrence-free survival (Liver RFS) curve in the expressions of the 4 candidate proteins by the 
Kaplan–Meier method. Blue and red lines indicate negative and positive expressions, respectively. Patients who were CNPY2 positive 
were significantly poorer in liver RFS compared with CNPY2 negative patients (p = 0.012, log-rank test). Patients with ANXA6 positive 
tended to be poorer, compared with ANXA6 negative patients (p = 0.099, log-rank test).
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pancreatic and bile duct cancer using this analysis [10, 
11]. Therefore, we considered that it could also be a useful 
tool for the detection of liver metastasis-related proteins 
of PanNEN.
At first, we selected 10 proteins from among 
identified proteins in PT and/or LT as candidates that 
showed more than a 2 fold difference in the expression 
levels between PT and LT. Among these 10 proteins, 
ANXA6, CNPY2, RAB11B and TUBB3, all of which 
showed higher expression in LT, were focused on 
according to the confirmation of protein expression by 
IHC. No characteristic heterogeneous staining was found 
in IHC for these candidate proteins. Of the four proteins, 
we found that CNPY2 could be novel liver metastasis-
correlated proteins of PanNEN. The present study 
demonstrated that the expression of CNPY2 and tumor 
size were independent predictors of liver RFS. Several 
previous studies revealed that the histological grade, 
Ki-67 labeling index, tumor size, vascular invasion and 
lymphatic invasion were correlated with recurrence and 
survival [17–19]. While positive data of liver metastasis-
correlated proteins could be seen, the overall survival 
indicated no correlation with the expression of CNPY2 
in this study. This might be because the population of the 
cohort was small and thus further studies on CNPY2 in a 
larger cohort are needed.
The function of CNPY2, previously called MIR-
interacting saposin-like protein (MSAP), putative secreted 
protein Zsig9 (ZSIG9) or transmembrane protein 4 
(TMEM4), is still unknown. There have been only a few 
published reports assessing the function of CNPY2. Guo 
et al. demonstrated that CNPY2 was regulated by hypoxia 
inducible factor (HIF)-1 alpha in human smooth muscle 
cells (SMC) and was a secreted angiogenic growth factor 
that promotes SMC migration, proliferation, and tissue 
revascularization by p53 inactivation [20, 21]. It has been 
reported that CNPY2 is related to esophageal squamous 
cell carcinoma (ESCC) [22], colorectal cancer (CRC) [23] 
and renal cancer [24]. No report on other malignancies 
including NETs has been published. In ESCC, patients 
with high expression of CNPY2, evaluated by IHC, 
showed significantly poor OS and RFS compared to 
those with low expression [22]. CNPY2 promoted tumor 
development through regulating p53 expression in CRC 
and renal cancer cells [23, 24]. Yan et al. demonstrated that 
knockdown of CNPY2 reversibly increased p53 activity 
using the colorectal cancer cell line HCT116 and suggested 
that CNPY2 plays a critical role in CRC development by 
enhancing cell growth, migration, and angiogenesis and by 
inhibiting apoptosis through negative regulation of the p53 
pathway [23]. P53 has been reported to show abnormal 
immunolabeling for pancreatic neuroendocrine carcinoma 
(NEC), but not for PanNEN [25, 26]. Further studies are 
needed to examine the relationship between CNPY2 
and p53 in PanNEN. The current study suggests that 
CNPY2 has potential as a biomarker for liver metastasis 
of PanNEN. CNPY2, which is a secreted protein, might 
have potential as a blood biomarker in liver metastasis of 
PanNEN because CNPY2 was detectable in murine blood 
plasma by enzyme-linked immunosorbent assay (ELISA) 
[35].
ANXA6 belongs to a family of calcium-dependent 
membrane and phospholipid binding proteins. ANXA6 
participates in membrane and cytoskeleton organization, 
cholesterol homeostasis, membrane trafficking, cell 
adhesion and signal transduction [27, 28]. In malignancies, 
Table 4: Univariate and multivariate analysis of clinicopathological factors and the candidate proteins in liver RFS
Factors (n = 62) Univariate analysis Multivariate analysis
HR (95%CI) p value HR (95%CI) p value
Function: NF vs. functioning 1.39 (0.76–2.65) 0.293
WHO 2017 Grade: G2/G3 vs. G1 2.03 (0.64–7.62) 0.235
WHO 2017: Grade G3 vs. G1/G2 3.50 (0.52–13.91) 0.117
Ki-67 ≥ 8.2%: yes vs. no 4.76 (1.51–16.18) 0.009 0.95 (0.20–5.36) 0.950
Tumor size ≥ 42 mm: yes vs. no 5.80 (1.69–18.46) 0.007 4.63 (1.03–23.23) 0.045
Lymph node metastasis Positive vs. Negative 1.43 (0.31–4.90) 0.610
Vascular invasion Positive vs. Negative 4.96 (1.48–22.38) 0.009 1.11 (0.14–7.94) 0.921
Lymphatic invasion Positive vs. Negative 4.37 (1.39–14.81) 0.012 3.84 (0.90–17.54) 0.069
Stage (ENETS): III/IV vs. I/II 1.43 (0.31–4.90) 0.610
ANXA6 4.77 (0.92–87.22) 0.064
CNPY2 5.60 (1.47–36.48) 0.010 6.19 (1.47–42.79) 0.011
RAB11B 0.97 (0.30–3.11) 0.961
TUBB3 1.34 (0.42–5.07) 0.631
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ANXA6 has been reported to play a role as a tumor 
suppressor in melanoma [29], breast cancer [30, 31] 
and gastric cancer [32]. In contrast, ANXA6 has been 
suggested to be a tumor promoter in cervical cancer [33], 
large cell lymphoma [28] and the stroma of pancreatic 
ductal adenocarcinoma [34]. There has been no report 
on the expression of ANXA6 in NETs. The results of the 
current study showed that PanNEN patients with ANXA6 
expression were likely to have poor liver RFS. ANXA6 
might also play a promotive role in the liver metastasis of 
PanNEN.
MATERIALS AND METHODS
Discovery stage
Patient selection and formalin-fixed paraffin-
embedded (FFPE) tissue samples for proteomic 
analysis
One hundred and eighteen patients with PanNEN 
who underwent surgical resection between 1994 and 2016 
at Tohoku University Hospital were examined. Twenty 
cases had synchronous or metachronous liver metastasis. 
Of these cases with liver metastasis, 7 cases had available 
FFPE samples of both PT and LT of PanNEN in an 
identical case, and were applied for proteomic analysis 
as the discovery set (Figure 1). Protein expression was 
compared between PT and LT by proteomic analysis. This 
study was approved by the Institutional Review Board of 
Tohoku University (the reference number 2017-1-437). 
Table 1 shows the patients’ characteristics at the discovery 
stage. The histological grade was determined according to 
the World Health Organization (WHO) 2017 of PanNENs 
[36]. The cohort contained patients with 5 synchronous 
and 2 metachronous liver metastases. In the histological 
grade, NET G2 and NET G3 included 4 and 3 cases, 
respectively. No patients with NEC G3 were included 
in the cohort. One case was gastrinoma, and the others 
were non-functioning PanNEN. Four patients died of the 
PanNEN. There was no patient with multiple endocrine 
neoplasia (MEN) in the cohort.
Laser microdissection (LMD) and protein extraction
LMD and protein extraction were performed as 
previously described [9, 10]. Briefly, 10 μm sections of the 
FFPE tissue samples were attached to DIRECTOR™ slides 
(Expression Pathology, MD, USA). After de-paraffinization 
with xylene, the samples were rehydrated with ethanol, 
stained with hematoxylin and then air-dried. Using a 
Leica LMD7000 (Leica Microsystems GmbH, Wetzler, 
Germany), approximately 30,000 tumor cells (8 mm2) were 
collected into the cap of a 0.2 ml polymerase chain reaction 
(PCR) tube. Peptide extraction was performed with a Liquid 
Tissue™ MS Protein Kit (Expression Pathology) according 
to the manufacturer’s instructions [37].
Nano HPLC/MS/MS analysis for proteomics
The dried peptide extracts (2–4 μg) were dissolved 
together in 20 μl sample solution [5% acetonitrile and 
0.1% trifluoroacetic acid (TFA)]. Each sample (10 μl) 
was injected into an EasynLC-1000 system (Thermo 
Fisher Scientific Inc., MA, USA) that was connected 
to an EASY-Spray column (25 cm length × C18 ODS 
75 μm, Thermo Fisher Scientific Inc.). Peptides were 
eluted with a 180 min gradient of 4% to 25% solvent B 
(0.1% formic acid in acetonitrile, v/v) in solvent A (0.1% 
formic acid in water, v/v) at a flow rate of 300-400 nl/
min. Peptides were then ionized and analyzed by a fusion 
mass spectrometer (Thermo Fisher Scientific Inc.) using a 
nano-spray source. High-resolution full scan MS spectra 
(from m/z 400–2,000) were acquired in the Orbitrap with 
resolution (R = 120,000 at m/z 400) and lock mass enabled 
(m/z at 445.12003 and 391.28429), followed by MS/MS 
fragmentation of the most intense ions for 3 sec in the 
linear ion trap with a collisionally activated dissociation 
(CID) energy of 35%. The exclusion duration for the data-
dependent scan was 0 s, and the isolation window was set 
at 10.0 m/z.
The MS/MS data were analyzed by sequence 
alignment using variable and static modifications by 
Mascot and Sequest algorithms. The protein database 
utilized was UniProt. The specific parameters for 
protein sequence database searching included oxidation 
(M), deamination (N, Q), acetylation (N-term.), and 
pyroglutamation (E) as variable modifications, and 
carbamidomethylation (C) as a static modification. Other 
parameters used in the data analysis were: two allowed 
missing cleavages, a mass error of 10 ppm for precursor 
ions, and 0.8 Da for fragment ions. Charge states of +2 
to +4 were considered for parent ions. If more than one 
spectrum was assigned to a peptide, only the spectrum 
with the highest Mascot score was selected for manual 
analysis. All peptides identified with a peptide score of 
Mascot > 20, and Sequest > 0.8 were manually examined 
using the protocol described previously [38].
Semi-quantitative comparison by spectral counting 
method
We compared the protein expression across all tissue 
samples from the results of the shotgun proteomics using the 
label-free spectral counting method, as previously described 
[9, 10, 14]. Fold changes in expressed proteins on a base 2 
logarithmic scale were evaluated with the protein ratio from 
the spectral counting (Rsc) [39]. Relative abundances of 
the identified proteins were investigated by the normalized 
spectral abundance factor (NSAF) [40]. Comparisons of 
protein expression between the pancreatic and liver tumors 
were evaluated with the spectral index (SpI), ranging 
from -1 to +1 [41]. SpI values close to 0 indicated nearly 
equal relative peptide abundance in the compared groups. 
Candidate proteins were selected to satisfy Rsc > 1 or < -1 
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and p value < 0.05 in G-test [42] and were narrowed down 
using NSAF and SpI values.
Immunohistochemistry
IHC was performed as previously described [9, 10, 
43]. Briefly, 4-μm FFPE tissue sections de-paraffinized 
with xylene and rehydrated with ethanol solutions and 
distilled water were heated in citrate acid buffer (10 
mmol/l citric acid, pH 6.0) at 121°C for 5 min with an 
autoclave or microwave oven for 15 min in citrate acid 
buffer (10 mM citric acid, pH 6.0) for antigen retrieval. 
Antibodies of ANXA6 (ab31026, dilution 1:25, Abcam, 
Cambridge, UK), CNPY2 (ab181217, dilution 1:50, 
Abcam), HIST1H3A (ab174712, dilution 1:20, Abcam), 
Microtubule-associated protein RP/EB family member 
1 (MAPRE1) (ab117821, dilution 1:250, Abcam,), 
Ras-related protein Rab-11A (RAB11A) (ab180778, 
dilution 1:50, Abcam), RAB11B (PA5-31348, dilution 
1:100, Thermo Fisher Scientific Inc., MA, USA), 
Signal peptidase complex catalytic subunit (SEC11A) 
(ab174794, dilution 1:100, Abcam), Tropomyosin alpha-1 
chain (TPM1) (ab55915, dilution 1:50, Abcam), TUBB3 
(ab18207, dilution 1:1000, Abcam), Vesicle-associated 
membrane protein 3 (VAMP3) (10702-1-AP, Proteintech, 
Inc., IL, USA) were used as the primary antibodies. 
The sections were incubated over night at 4°C with one 
of the primary antibodies. After blocking endogenous 
peroxidase with methanol containing 0.3% hydrogen 
peroxidase, the labeled antigens were identified by an 
EnVision+ Sytem-HRP (DAKO, Glostrup, Denmark) and 
visualized by 3, 3’-diaminobenzidine tetrahydrochloride 
as a chromogen. The sections were lightly counterstained 
with hematoxylin.
Two of the authors (M.S., T.S.) completely reviewed 
all slides of the immunostained sections in each sample 
and classified the cases into two groups. We defined ≥ 10% 
tumor cells with staining of protein as positive expression, 
and < 10% tumor cells as negative expression. PT and LT 
samples in the discovery stage and pancreatic tumors of 
PanNEN in all cases except for those without available 
FFPE samples in the next clinicopathological analysis 
stage were examined by IHC for candidate proteins.
Clinicopathological analysis stage
Of 118 patients with PanNEN, pancreatic tumors 
of 70 patients with available FFPE tissue were evaluated 
by IHC for protein expression of the candidate proteins. 
One patient with MEN type1 was included in the analyzed 
cohort. The duration of follow-up was calculated from the 
date of initial surgery to the date of death or last follow-up. 
Liver RFS was defined as the length of time that patients 
survived without initial liver metastasis after resection of the 
primary pancreatic tumor. Eight patients with synchronous 
liver metastasis were excluded from the analysis of OS and 
liver RFS (Figure 1). Liver metastasis-correlated factors 
were identified from clinicopathological factors including 
candidate proteins by univariate and multivariate analyses 
with a Cox proportional hazards model.
Statistical analysis
JMP software version 13.0 (SAS Institute, NC, 
USA) was used for all analyses. Significance was 
calculated using Fisher’s exact test, Pearson’s χ2-test for 
categorical variates and Mann–Whitney U test, Kruskal–
Wallis test for continuous variates. In the univariate 
analysis, OS and liver RFS rates were calculated by the 
Kaplan–Meier method and compared using the log-rank 
test. Univariate and multivariate analyses were performed 
using a Cox proportional hazards model to examine 
potential factors influencing the liver RFS. P < 0.05 was 
considered statistically significant.
CONCLUSIONS
We have demonstrated for the first time that 
CNPY2 is a novel liver metastasis-correlated factor of 
PanNEN. Also, ANXA6 might affect the liver metastasis 
of PanNEN. Further studies are needed to elucidate the 
functions of CNPY2 and ANXA6 in PanNEN.
Abbreviations
AUC: area under the curve; ANXA6: Annexin A6; 
CID: collisionally activated dissociation; CNPY2: the canopy 
FGF signaling regulator 2; CRC: colorectal cancer; ENETS: 
European Neuroendocrine Tumor Society; ESCC: esophageal 
squamous cell carcinoma; FFPE: formalin-fixed paraffin-
embedded; HIF-1: hypoxia inducible factor -1; HIST1H3A: 
Histone H3.1; IHC: immunohistochemistry; KEGG: 
Kyoto Encyclopedia of Genes and Genomes; LC-MS/MS: 
liquid chromatography-tandem mass spectrometry; LMD: 
laser capture microdissection; LT: metastatic liver tumor; 
MAPRE1: microtubule-associated protein RP/EB family 
member 1; MEN: multiple endocrine neoplasia; MRLC: 
myosin regulatory light chain; MS: mass spectrometry; 
MSAP: MIR-interacting saposin-like protein; NET: 
neuroendocrine tumors; NEC: neuroendocrine carcinoma; 
NSAF: the normalized spectral abundance factor; OS: overall 
survival; PanNEN: pancreatic neuroendocrine neoplasm; 
PT: primary pancreatic tumor; RAB11A: Ras-related protein 
Rab-11A; RAB11B: Ras-related protein Rab-11B; RAB25: 
Ras-related protein Rab-25; RFS: recurrence-free survival; 
ROC: receiver operating characteristic; Rsc: the protein ratio 
from spectral counting; PCR: polymerase chain reaction; 
SEC11A: signal peptidase complex catalytic subunit; 
SEER: the surveillance, epidemiology, and end results; SpI: 
spectral index; TMEM4: transmembrane protein 4; TFA: 
trifluoroacetic acid; TPM1: tropomyosin alpha-1 chain; 
TUBB3: tubulin beta-3 chain; VAMP3: Vesicle-associated 
membrane protein 3; WHO: World Health Organization; 
ZSIG9: putative secreted protein Zsig9.
Oncotarget24301www.oncotarget.com
Author contributions
MS and MM designed the research. MS, YK and 
TS performed the experiment. TT, SA and YS technically 
supported the experiments. MS and MM wrote the paper. 
MI, TH, SA, YS, NS, HO, HH, TM, KN, FM, TN, KI, HS 
and MU reviewed the manuscript and revised it critically 
for important intellectual content. MM integrated the entire 
study. All authors read and approved the final manuscript.
ACKNOWLEDGMENTS
We thank Yoshihiro Sato, Emiko Shibuya and 
Keiko Inabe in Department of Surgery, Tohoku University 
Graduate School of Medicine, who provided kind support 
in this study.
CONFLICTS OF INTEREST
The authors declare that they have no conflicts of 
interest.
FUNDING
This work was supported by Japan Society for 
the Promotion of Science Grant-in-Aid for Scientific 
Research (C: 15K10179) (MM) and the Pancreas Research 
Foundation of Japan, Grants-in-Aid for Pancreas Research 
2014 (SA).
REFERENCES
1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares 
JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans 
DB. One hundred years after “carcinoid”: epidemiology of 
and prognostic factors for neuroendocrine tumors in 35,825 
cases in the United States. J Clin Oncol. 2008; 26: 3063–72. 
https://doi.org/10.1200/jco.2007.15.4377.
2. Ito T, Igarashi H, Nakamura K, Sasano H, Okusaka T, 
Takano K, Komoto I, Tanaka M, Imamura M, Jensen RT, 
Takayanagi R, Shimatsu A. Epidemiological trends of 
pancreatic and gastrointestinal neuroendocrine tumors in 
Japan: a nationwide survey analysis. J Gastroenterol. 2015; 
50: 58–64. https://doi.org/10.1007/s00535-014-0934-2.
3. Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, 
Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, 
Davidson B, Siegler M, Caplin M, et al, and Working Group 
on Neuroendocrine Liver Metastases. Recommendations 
for management of patients with neuroendocrine liver 
metastases. Lancet Oncol. 2014; 15: e8–21. https://doi.
org/10.1016/s1470-2045(13)70362-0.
4. Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, 
Dromain C, Schlumberger M, Pocard M, Boige V, Miquel 
C, Baudin E. Liver resection (and associated extrahepatic 
resections) for metastatic well-differentiated endocrine 
tumors: a 15-year single center prospective study. Surgery. 
2003; 133: 375–82. https://doi.org/10.1067/msy.2003.114.
5. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney 
DM, Que FG. Surgical treatment of neuroendocrine 
metastases to the liver: a plea for resection to increase 
survival. J Am Coll Surg. 2003; 197: 29–37. https://doi.
org/10.1016/s1072-7515(03)00230-8.
6. Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy 
SK, Gamblin TC, Celinksi SA, Kooby DA, Staley CA, 
Stokes JB, Chu CK, Ferrero A, Schulick RD, et al. 
Surgical management of hepatic neuroendocrine tumor 
metastasis: results from an international multi-institutional 
analysis. Ann Surg Oncol. 2010; 17: 3129–36. https://doi.
org/10.1245/s10434-010-1154-5.
7. Maxwell JE, Sherman SK, O’Dorisio TM, Bellizzi AM, 
Howe JR. Liver-directed surgery of neuroendocrine 
metastases: What is the optimal strategy? Surgery. 2016; 
159: 320–33. https://doi.org/10.1016/j.surg.2015.05.040.
8. Zhang Y, Ye Y, Shen D, Jiang K, Zhang H, Sun W, Zhang J, Xu 
F, Cui Z, Wang S. Identification of transgelin-2 as a biomarker 
of colorectal cancer by laser capture microdissection and 
quantitative proteome analysis. Cancer Sci. 2010; 101: 523–29.
9. Takadate T, Onogawa T, Fujii K, Motoi F, Mikami S, 
Fukuda T, Kihara M, Suzuki T, Takemura T, Minowa 
T, Hanagata N, Kinoshita K, Morikawa T, et al. Nm23/
nucleoside diphosphate kinase-A as a potent prognostic 
marker in invasive pancreatic ductal carcinoma identified 
by proteomic analysis of laser micro-dissected formalin-
fixed paraffin-embedded tissue. Clin Proteomics. 2012; 9: 
8. https://doi.org/10.1186/1559-0275-9-8.
10. Takadate T, Onogawa T, Fukuda T, Motoi F, Suzuki T, 
Fujii K, Kihara M, Mikami S, Bando Y, Maeda S, Ishida 
K, Minowa T, Hanagata N, et al. Novel prognostic protein 
markers of resectable pancreatic cancer identified by 
coupled shotgun and targeted proteomics using formalin-
fixed paraffin-embedded tissues. Int J Cancer. 2013; 132: 
1368–82. https://doi.org/10.1002/ijc.27797.
11. Maeda S, Morikawa T, Takadate T, Suzuki T, Minowa T, 
Hanagata N, Onogawa T, Motoi F, Nishimura T, Unno M. 
Mass spectrometry-based proteomic analysis of formalin-
fixed paraffin-embedded extrahepatic cholangiocarcinoma. 
J Hepatobiliary Pancreat Sci. 2015; 22: 683–91. https://doi.
org/10.1002/jhbp.262.
12. Park J, Lee E, Park KJ, Park HD, Kim JW, Woo HI, Lee 
KH, Lee KT, Lee JK, Park JO, Park YS, Heo JS, Choi 
SH, et al. Large-scale clinical validation of biomarkers 
for pancreatic cancer using a mass spectrometry-based 
proteomics approach. Oncotarget. 2017; 8: 42761–71. 
https://doi.org/10.18632/oncotarget.17463.
13. Shen Z, Wang B, Luo J, Jiang K, Zhang H, Mustonen 
H, Puolakkainen P, Zhu J, Ye Y, Wang S. Global-scale 
profiling of differential expressed lysine acetylated proteins 
in colorectal cancer tumors and paired liver metastases. J 
Proteomics. 2016; 142: 24–32. https://doi.org/10.1016/j.
jprot.2016.05.002.
Oncotarget24302www.oncotarget.com
14. Kawamura T, Nomura M, Tojo H, Fujii K, Hamasaki H, 
Mikami S, Bando Y, Kato H, Nishimura T. Proteomic 
analysis of laser-microdissected paraffin-embedded tissues: 
(1) Stage-related protein candidates upon non-metastatic 
lung adenocarcinoma. J Proteomics. 2010; 73: 1089–99. 
https://doi.org/10.1016/j.jprot.2009.11.011.
15. Alkatout I, Friemel J, Sitek B, Anlauf M, Eisenach PA, 
Stuhler K, Scarpa A, Perren A, Meyer HE, Knoefel WT, 
Kloppel G, Sipos B. Novel prognostic markers revealed by 
a proteomic approach separating benign from malignant 
insulinomas. Mod Pathol. 2015; 28: 69–79. https://doi.
org/10.1038/modpathol.2014.82.
16. Song YL, Yu R, Qiao XW, Bai CM, Lu CM, Xiao Y, Zhong 
DR, Chen J, Zhao YP, Zhang TP, Song TT, Gao HL, Wan 
YH, et al. Prognostic relevance of UCH-L1 and alpha-
internexin in pancreatic neuroendocrine tumors. Sci Rep. 
2017; 7: 2205. https://doi.org/10.1038/s41598-017-02051-1.
17. Jamali M, Chetty R. Predicting prognosis in gastroentero-
pancreatic neuroendocrine tumors: an overview and the 
value of Ki-67 immunostaining. Endocr Pathol. 2008; 19: 
282–8. https://doi.org/10.1007/s12022-008-9044-0.
18. Nanno Y, Toyama H, Otani K, Asari S, Goto T, Terai S, 
Ajiki T, Zen Y, Fukumoto T, Ku Y. Microscopic venous 
invasion in patients with pancreatic neuroendocrine 
tumor as a potential predictor of postoperative recurrence. 
Pancreatology. 2016; 16: 882–7. https://doi.org/10.1016/j.
pan.2016.06.008.
19. Ricci C, Casadei R, Taffurelli G, Pacilio CA, Campana D, 
Ambrosini V, Donatella S, Minni F. Sporadic Small (≤20 
mm) Nonfunctioning Pancreatic Neuroendocrine Neoplasm: 
is the Risk of Malignancy Negligible When Adopting a 
More Conservative Strategy? A Systematic Review and 
Meta-analysis. Ann Surg Oncol. 2017; 24: 2603–10.
20. Guo J, Mihic A, Wu J, Zhang Y, Singh K, Dhingra S, 
Weisel RD, Li RK. Canopy 2 attenuates the transition 
from compensatory hypertrophy to dilated heart failure in 
hypertrophic cardiomyopathy. Eur Heart J. 2015; 36: 2530–
40. https://doi.org/10.1093/eurheartj/ehv294.
21. Guo J, Zhang Y, Mihic A, Li SH, Sun Z, Shao Z, Wu J, 
Weisel RD, Li RK. A secreted protein (Canopy 2, CNPY2) 
enhances angiogenesis and promotes smooth muscle cell 
migration and proliferation. Cardiovasc Res. 2015; 105: 
383–93. https://doi.org/10.1093/cvr/cvv010.
22. He JZ, Wu ZY, Wang SH, Ji X, Yang CX, Xu XE, Liao 
LD, Wu JY, Li EM, Zhang K, Xu LY. A decision tree-based 
combination of ezrin-interacting proteins to estimate the 
prognostic risk of patients with esophageal squamous cell 
carcinoma. Hum Pathol. 2017; 66: 115–25. https://doi.
org/10.1016/j.humpath.2017.06.003.
23. Yan P, Gong H, Zhai X, Feng Y, Wu J, He S, Guo J, 
Wang X, Guo R, Xie J, Li RK. Decreasing CNPY2 
Expression Diminishes Colorectal Tumor Growth and 
Development through Activation of p53 Pathway. Am J 
Pathol. 2016; 186: 1015–24. https://doi.org/10.1016/j.
ajpath.2015.11.012.
24. Taniguchi H, Ito S, Ueda T, Morioka Y, Kayukawa N, Ueno 
A, Nakagawa H, Fujihara A, Ushijima S, Kanazawa M, 
Hongo F, Ukimura O. CNPY2 promoted the proliferation 
of renal cell carcinoma cells and increased the expression of 
TP53. Biochem Biophys Res Commun. 2017; 485: 267–71. 
https://doi.org/10.1016/j.bbrc.2017.02.095.
25. Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, 
Morgan R, de Wilde RF, Maitra A, Hicks J, Demarzo AM, 
Shi C, Sharma R, Laheru D, et al. Small cell and large cell 
neuroendocrine carcinomas of the pancreas are genetically 
similar and distinct from well-differentiated pancreatic 
neuroendocrine tumors. Am J Surg Pathol. 2012; 36: 173–
84. https://doi.org/10.1097/PAS.0b013e3182417d36.
26. Girardi DM, Silva ACB, Rego JFM, Coudry RA, 
Riechelmann RP. Unraveling molecular pathways of 
poorly differentiated neuroendocrine carcinomas of the 
gastroenteropancreatic system: A systematic review. Cancer 
Treat Rev. 2017; 56: 28–35. https://doi.org/10.1016/j.
ctrv.2017.04.002.
27. Grewal T, Koese M, Rentero C, Enrich C. Annexin 
A6-regulator of the EGFR/Ras signalling pathway and 
cholesterol homeostasis. Int J Biochem Cell Biol. 2010; 42: 
580–4. https://doi.org/10.1016/j.biocel.2009.12.020.
28. Tressler RJ, Yeatman T, Nicolson GL. Extracellular annexin 
VI expression is associated with divalent cation-dependent 
endothelial cell adhesion of metastatic RAW117 large-cell 
lymphoma cells. Exp Cell Res. 1994; 215: 395–400. https://
doi.org/10.1006/excr.1994.1358.
29. Francia G, Mitchell SD, Moss SE, Hanby AM, Marshall JF, 
Hart IR. Identification by differential display of annexin-VI, 
a gene differentially expressed during melanoma 
progression. Cancer Res. 1996; 56: 3855–8.
30. Sakwe AM, Koumangoye R, Guillory B, Ochieng J. Annexin 
A6 contributes to the invasiveness of breast carcinoma cells 
by influencing the organization and localization of functional 
focal adhesions. Exp Cell Res. 2011; 317: 823–37. https://doi.
org/10.1016/j.yexcr.2010.12.008.
31. Koese M, Rentero C, Kota BP, Hoque M, Cairns R, 
Wood P, Vila de Muga S, Reverter M, Alvarez-Guaita A, 
Monastyrskaya K, Hughes WE, Swarbrick A, Tebar F, et al. 
Annexin A6 is a scaffold for PKCalpha to promote EGFR 
inactivation. Oncogene. 2013; 32: 2858–72. https://doi.
org/10.1038/onc.2012.303.
32. Wang X, Zhang S, Zhang J, Lam E, Liu X, Sun J, Feng L, 
Lu H, Yu J, Jin H. Annexin A6 is down-regulated through 
promoter methylation in gastric cancer. Am J Transl Res. 
2013; 5: 555–62.
33. Lomnytska MI, Becker S, Bodin I, Olsson A, Hellman K, 
Hellstrom AC, Mints M, Hellman U, Auer G, Andersson 
S. Differential expression of ANXA6, HSP27, PRDX2, 
NCF2, and TPM4 during uterine cervix carcinogenesis: 
diagnostic and prognostic value. Br J Cancer. 2011; 104: 
110–9. https://doi.org/10.1038/sj.bjc.6605992.
34. Leca J, Martinez S, Lac S, Nigri J, Secq V, Rubis M, Bressy 
C, Serge A, Lavaut MN, Dusetti N, Loncle C, Roques J, 
Oncotarget24303www.oncotarget.com
Pietrasz D, et al. Cancer-associated fibroblast-derived 
annexin A6+ extracellular vesicles support pancreatic 
cancer aggressiveness. J Clin Invest. 2016; 126: 4140–56. 
https://doi.org/10.1172/jci87734.
35. Hatta K, Guo J, Ludke A, Dhingra S, Singh K, Huang 
ML, Weisel RD, Li RK. Expression of CNPY2 in mouse 
tissues: quantification and localization. PLoS One. 2014; 
9: e111370. https://doi.org/10.1371/journal.pone.0111370.
36. Lloyd RV, Klöppel G, Rosai J. WHO Classification of 
Tumours of Endocrine Organs WHO/IARC Classification 
of Tumours, 4th Edition, Volume 10. 2017.
37. Prieto DA, Hood BL, Darfler MM, Guiel TG, Lucas 
DA, Conrads TP, Veenstra TD, Krizman DB. Liquid 
Tissue: proteomic profiling of formalin-fixed tissues. 
Biotechniques. 2005; 38: 32–35.
38. Chen Y, Kwon SW, Kim SC, Zhao Y. Integrated approach 
for manual evaluation of peptides identified by searching 
protein sequence databases with tandem mass spectra. J 
Proteome Res. 2005; 4: 998–1005. https://doi.org/10.1021/
pr049754t.
39. Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, 
Mendoza A, Sevinsky JR, Resing KA, Ahn NG. Comparison 
of label-free methods for quantifying human proteins by 
shotgun proteomics. Mol Cell Proteomics. 2005; 4: 1487–
502. https://doi.org/10.1074/mcp.M500084-MCP200.
40. Paoletti AC, Parmely TJ, Tomomori-Sato C, Sato S, Zhu 
D, Conaway RC, Conaway JW, Florens L, Washburn MP. 
Quantitative proteomic analysis of distinct mammalian 
Mediator complexes using normalized spectral abundance 
factors. Proc Natl Acad Sci U S A. 2006; 103: 18928–33. 
https://doi.org/10.1073/pnas.0606379103.
41. Fu X, Gharib SA, Green PS, Aitken ML, Frazer DA, Park 
DR, Vaisar T, Heinecke JW. Spectral index for assessment 
of differential protein expression in shotgun proteomics. J 
Proteome Res. 2008; 7: 845–54. https://doi.org/10.1021/
pr070271+.
42. Zhang B, VerBerkmoes NC, Langston MA, Uberbacher 
E, Hettich RL, Samatova NF. Detecting differential 
and correlated protein expression in label-free shotgun 
proteomics. J Proteome Res. 2006; 5: 2909–18. https://doi.
org/10.1021/pr0600273.
43. Aoki S, Mizuma M, Takahashi Y, Haji Y, Okada R, Abe 
T, Karasawa H, Tamai K, Okada T, Morikawa T, Hayashi 
H, Nakagawa K, Motoi F, et al. Aberrant activation of 
Notch signaling in extrahepatic cholangiocarcinoma: 
clinicopathological features and therapeutic potential for 
cancer stem cell-like properties. BMC Cancer. 2016; 16: 
854. https://doi.org/10.1186/s12885-016-2919-4.
